6533b7d3fe1ef96bd1261332
RESEARCH PRODUCT
Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.
Linda T. VahdatMaria Martinez GarciaEva CiruelosBarbara RomagnoliSonia Pernas SimonJavier CortesPatricia Gomez PardoFoluso O. AdemuyiwaPeter A. KaufmanCristina HernandoSara López-tarruellaIngrid A. MayerJose Alejandro Perez-fidalgoLuis MansoTimothy J. PluardMarta Gil-martinDebra BarkerKatherine N. WeilbaecherMiguel Martínsubject
Cancer ResearchCXCR4 antagonistbusiness.industryAntagonistHER2 negativemedicine.diseaseCXCR4Metastatic breast cancer03 medical and health scienceschemistry.chemical_compoundChemokine receptor0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisCancer researchMedicinebusiness030215 immunologyEribulindescription
2606 Background: Balixafortide (B) is a potent antagonist of the chemokine receptor CXCR4. Preclinical evidence suggests that disrupting CXCR4 dependent pathways prevents development of breast cancer metastases, enhances the cytotoxic effect of chemotherapy and immunotherapy, and counteracts tumor cell evasion of the immune system. Encouraging safety and efficacy data were published recently from the ongoing Phase 1 trial investigating B + eribulin (E) in patients with HER2 negative MBC (Pernas S. et al. Lancet Oncol. 2018; 19: 812−24). The objective response rate, median progression free survival and median overall survival (OS) for the expanded cohort (EC) and the overall efficacy population (OEP) were 37.5% and 29.6%, 6.2 months and 4.5 months, and 18 months and 16.8 months, respectively. Here we report the 18 and 24 months landmark OS data from this trial. Methods: This trial enrolled 56 patients with HER2-negative, CXCR4-positive MBC, previously treated with 1−3 chemotherapy regimens for MBC. A 3+3 dose escalation design was used, followed by an EC. All cohorts received E on days 2 and 9, and B on days 1−3 and 8−10 of 21 day cycles. The association between various baseline biomarkers and treatment outcomes including OS is currently being investigated in a multivariate analysis (MVA). Results: Landmark survival data for the trial are shown in the table. Clinical trial information: NCT01837095. Conclusions: Landmark 18 months and 24 months OS data are consistent with the positive trend of all efficacy read-outs observed in this study and safety information is consistent with what was previously reported. Although inter-trial comparisons should be interpreted with caution, these survival rates, especially for the EC, are higher than those reported for eribulin monotherapy in similar MBC populations. These promising results suggest that B + E could potentially provide a new treatment option in heavily pre-treated patients with HER2 negative MBC and this is currently being investigated in a pivotal, randomized trial.[Table: see text]
year | journal | country | edition | language |
---|---|---|---|---|
2019-05-20 | Journal of Clinical Oncology |